PD-1 blockade induces responses by inhibiting adaptive immune resistance

被引：0

作者：

Paul C. Tumeh

Christina L. Harview

Jennifer H. Yearley

I. Peter Shintaku

Emma J. M. Taylor

Lidia Robert

Bartosz Chmielowski

Marko Spasic

Gina Henry

Voicu Ciobanu

Alisha N. West

Manuel Carmona

Christine Kivork

Elizabeth Seja

Grace Cherry

Antonio J. Gutierrez

Tristan R. Grogan

Christine Mateus

Gorana Tomasic

John A. Glaspy

Ryan O. Emerson

Harlan Robins

Robert H. Pierce

David A. Elashoff

Caroline Robert

Antoni Ribas

机构：

[1] University of California Los Angeles (UCLA),

[2] Jonsson Comprehensive Cancer Center,undefined

[3] Merck & Co,undefined

[4] Gustave Roussy and INSERM U981,undefined

[5] Villejuif,undefined

[6] Paris Sud,undefined

[7] France,undefined

[8] Adaptive Biotechnologies,undefined

[9] Fred Hutchinson Cancer Research Center,undefined

来源：

Nature | 2014年 / 515卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The dynamics of T-cell responses are investigated in tumour tissue from patients with advanced melanoma who were treated with a PD-1-blocking monoclonal antibody, revealing that clinical efficacy of the treatment correlates with increased frequencies of pre-existing CD8+ T cells and PD-1 and PD-L1 expression.

引用

页码：568 / 571

页数：3

共 50 条

[21] Gut bacteria modulate responses to PD-1 blockade
Killock, David
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (01) : 6 - 6
[22] Clinical-stage monitoring of adaptive tumor resistance to PD-1 checkpoint blockade
Smalley, M.
Shanthappa, B.
Gertje, H.
Lawson, M.
Ulaganathan, B.
Thayakumar, A.
Maciejko, L.
Radhakrishnan, P.
Biswas, M.
Thiyagarajan, S.
Majumder, B.
Gopinath, K.
Babu, G.
Goldman, A.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E4 - E5
[23] Gut bacteria modulate responses to PD-1 blockade
David Killock
Nature Reviews Clinical Oncology, 2018, 15 : 7 - 7
[24] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, Jie
Gao, Zhitao
Li, Xiang
Dong, Liang
Han, Weidong
Nie, Jing
ONCOTARGET, 2017, 8 (66) : 110693 - 110707
[25] Acquired resistance to PD-1 blockade in NSCLC.
Schoenfeld, Adam Jacob
Rizvi, Hira
Memon, Danish
Luo, Jia
Preeshagul, Isabel Ruth
Sauter, Jennifer L.
Plodkowski, Andrew J.
Vanderbilt, Chad
Miller, Martin L.
Hellmann, Matthew David
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Mechanisms of primary resistance to PD-1 checkpoint blockade
Krogsgaard, Michelle
Moogk, Duane
Li, Kaitao
Yuan, Zhou
Osman, Iman
Weber, Jeffrey S.
Zhu, Cheng
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
[27] PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine
Zhang, Xinji
Shi, Xiaojun
Li, Jinlong
Mo, Lijun
Hu, Zhiming
Gao, Jimin
Wu, Shihao
Long, Zhaolin
JOURNAL OF CANCER, 2018, 9 (23): : 4374 - 4381
[28] Loss of Tumor Intrinsic RIPK1, Antitumor Immune Responses, and the Efficacy of PD-1 Blockade
Teng, F.
Wang, P.
Li, Y.
Yuan, J.
Yin, T.
Shi, X.
Xu, J.
Liu, C.
Yu, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E403 - E403
[29] Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial
Demaria, Sandra
Romano, Emanuela
Brackstone, Muriel
Formenti, Silvia C.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
[30] Dual PD-1 and VEGFR-2 blockade induces vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma.
Datta, Meenal
Shigeta, Kohei
Hato, Tai
Kitihara, Shuji
Chen, Ivy X.
Matsui, Aya
Mamessier, Hiroto Kikuchi Emilie
Aoki, Shuichi
Ramjiawan, Rakesh R.
Ochiai, Hiroki
Bardeesy, Nabeel
Huang, Peigen
Jain, Rakesh K.
Cobbold, Mark
Zhu, Andrew X.
Duda, Dan G.
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 130 - 130

← 1 2 3 4 5 →